The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Always room for more pain medications/formulations for cancer patients The sublingual fentanyl approach is a highly desirable formulation due to rapid onset of action ie BTP control The concern is the faster they can be made to act, the more the abuse potential by non cancer patients
Higher doses of conventional chemotherapy agent , improves outcome in AML A large population of AML patients are elderly The "higher the dose of chemo, the better" concept still applies to some malignancies
Satistics are usually used to reveal dramatic differences Patients often misinterpret relative differences for absolute ones patients are willing to do a lot more to get any benefit in cancer outcome
Many studies support EGFR response correlates with rash Many attempts to actually increase the incidence of rash Most patients will use the EGFR treatments despite the rash
This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the...
Recent Cell Genesys vaccine trial for prostate cancer fails
The trial not only shows lack of efficacy, but possible harm from the vaccine arm of the trial
We are facing an ever increasing expense of treating cancver
The so called targeted drugs are the big price items
The recent discovery of theses drugs have sometimes been out of order with understanding their activity
Be cautious of vaccine approaches to cancer No cancer has had success with the use of vaccine therapy We are far from figuring out the reason for failure of vaccines to treat cancer